World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Shetty S, Suvarna R, Ambrose Fistus V, Modi S, Pappachan JM. Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis. World J Hepatol 2025; 17(5): 105706 [PMID: 40501478 DOI: 10.4254/wjh.v17.i5.105706]
URL:	https://www.wjgnet.com/1948-5182/full/v17/i5/105706.htm

(94) (80) (0) (0) (0) (7) (2391) (7)

Number	Citing Articles
1	Luo Lv, Yuli Guo, Yubo Ren, Bao Li, Xiaofang Li, Qinghua Han, Haixiong Wang. Interpretable machine learning of non-traditional lipid indices for diagnostic classification of CHD in patients with comorbid MASLD and T2DM: a multicenter study. Frontiers in Nutrition 2026; 13 doi: 10.3389/fnut.2026.1803996
2	Matheus Henrique Gonçalves de Souza, Pedro Miguel Mattos Nogueira, Cristiane Alves Villela-Nogueira. Metabolic dysfunction-associated steatotic liver disease and diabetes: Together against the heart. World Journal of Hepatology 2025; 17(9): 109737 doi: 10.4254/wjh.v17.i9.109737 Abstract(93) \| Core Tip(77) \| Full Article(HTML)(252) \| Full Article (PDF)-397K(82) \| Full Article with Cover (PDF)-728K(77) \| Full Article (XML)-78K(35) \| Audio-616K(12) \| Peer-Review Report-253K(28) \| Answering Reviewers-123K(43) \| Times Cited (1) \| Total Visits (446) \| Open
3	Chunxia Deng, Ling Feng, Tingting Li, Suosu Wei, Huiming Zhu, Jie Lu. Development and external validation of an interpretable machine learning model for diagnosing coronary heart disease in patients with type 2 diabetes and MASLD. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1830594
4	Kamlesh Khunti, Francesco Zaccardi, Roopa Mehta, Edward W Gregg, Shivani Misra. Epidemiology of cardiometabolic multiple long-term conditions. The Lancet 2026; doi: 10.1016/S0140-6736(26)00606-9
5	Abul Bashar Mohammad Kamrul-Hasan, Sanja Borozan, Sweekruti Jena, Lakshmi Nagendra, Deep Dutta, Saptarshi Bhattacharya, Md Saiful Islam, Joseph M Pappachan. Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review. World Journal of Gastrointestinal Pharmacology and Therapeutics 2025; 16(3): 110709 doi: 10.4292/wjgpt.v16.i3.110709 Abstract(125) \| Core Tip(129) \| Full Article(HTML)(877) \| Full Article (PDF)-567K(152) \| Full Article with Cover (PDF)-819K(71) \| Full Article (XML)-161K(47) \| Audio-625K(10) \| Peer-Review Report-261K(48) \| Answering Reviewers-204K(53) \| Supplementary Material-571K(48) \| Times Cited (3) \| Total Visits (1383) \| Open
6	Peter Chinedu Agu, Appolonia Fulgence Yudas, Jun Lu. Dual-Target Insight into Drug Discovery from Natural Products as Modulators of GLP-1 and the TXNIP–Thioredoxin Antioxidant System in Metabolic Syndrome. Antioxidants 2025; 14(11) doi: 10.3390/antiox14111364
7	Amedeo Lonardo, Ralf Weiskirchen. PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD. Exploration of Digestive Diseases 2025; 4 doi: 10.37349/edd.2025.100590

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.